ACLA
Called the Coalition for Effective Diagnostics, the organization has called on lawmakers to pass legislation revamping diagnostics regulation, including oversight of LDTs.
While Congress has protected labs from PAMA cuts via a series of one-year delays, this has locked lab prices at 2016 levels, heightening the urgency for a permanent fix.
Retirements and the outcomes of a handful of close races could reshape congressional committees tasked with oversight of issues important to labs.
The rule could force labs to shed tests deemed nonessential to their institutions' missions as well as influence decisions around instrumentation and vendor choices.
Top Five Articles on 360Dx Last Week: Potential Shake-up in Mass Spec Space; Agilent Layoffs; More
Last week, readers were most interested in a story about a potential shift in the mass spec space resulting from the FDA's final rule on LDTs.